Table 4

Odds ratios for associations between biomarker levels (baseline and changes from baseline to week 4) and outcome measures of fatigue (FACIT-F) and health-related quality of life (SF-36) at week 14 for the training and test golimumab/golimumab + MTX datasets

FACIT-F

SF-36 PCS

SF-36 MCS


OR

P

OR

P

OR

P


Training subset

Baseline

von Willebrand factor

0.380

0.021

0.427

0.039

0.370

0.019

Change from baseline to week 4

ENRAGE (S100A12)

0.578

0.053

0.549

0.044

0.603

0.070

Matrix metalloproteinase-3

0.529

0.041

0.621

0.122

1.000

0.999

Test subset

Baseline

Matrix metalloproteinase-3

1.233

0.035

0.922

0.409

0.972

0.775

Tissue inhibitor of metalloproteinase-1

0.925

0.843

0.375

0.017

0.798

0.567

Change from baseline to week 4

C-reactive protein

0.879

0.122

0.772

0.003

0.833

0.033

Matrix metalloproteinase-3

0.893

0.522

0.811

0.248

0.615

0.010

All data combined

Baseline

α1-antitrypsin

1.206

0.479

0.567

0.037

1.230

0.436

Intracellular adhesion molecule-1

1.166

0.484

0.611

0.046

1.451

0.117

Tissue inhibitor of metalloprotienases-1

0.833

0.583

0.342

0.002

0.843

0.610

von Willebrand factor

0.949

0.775

0.628

0.017

0.760

0.146

Change from baseline to week 4

C-reactive protein

0.910

0.176

0.831

0.011

0.940

0.370

ENRAGE (S100A12)

0.761

0.040

0.710

0.011

0.821

0.135

Interleukin-6

0.953

0.543

0.846

0.039

0.965

0.651

Matrix metalloprotienase-3

0.810

0.173

0.784

0.121

0.669

0.013


Odds ratios show association between biomarker levels (baseline or changes from baseline to week 4) and whether FACIT-F, SF-36 mental component summary score, or SF-36 physical component summary score was above or below the median. Only biomarkers for which at least one association was <0.05 are shown. FACIT-F, Functional Assessment of Chronic Illness Therapy -Fatigue; SF-36, 36-question Short Form Survey; OR, odds ratio; MCS, mental component summary score; PCS, physical component summary score.

Visvanathan et al. Arthritis Research & Therapy 2010 12:R211   doi:10.1186/ar3188

Open Data